Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (111-120 of 250) with videos related to

Pageof 25
Sort By:
Frontiers in Oncology|November 29, 2023
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myelomaLaura Rosiñol, Benjamin Hebraud, Albert Oriol, et al.
Haematologica|May 13, 2014
Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathiesLucía López-Corral, Luis Antonio Corchete, María Eugenia Sarasquete, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple MyelomaA Keith Stewart, Meletios A Dimopoulos, Tamás Masszi, et al.
Haematologica|November 8, 2011
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable diseaseLaura Rosiñol, Ramón García-Sanz, Juan José Lahuerta, et al.
Cancer|April 17, 2024
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myelomaAttaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, et al.
American Journal of Hematology|January 28, 2022
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trialEvangelos Terpos, Meletios A Dimopoulos, Mario Boccadoro, et al.
Haematologica|June 13, 2015
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trialRamón García-Sanz, Albert Oriol, María J Moreno, et al.
Cancer|January 31, 2013
Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab)Josep-Maria Ribera, Olga García, Carlos Grande, et al.
The Lancet. Oncology|July 13, 2016
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trialMaría-Victoria Mateos, Miguel-Teodoro Hernández, Pilar Giraldo, et al.
Acta Haematologica|May 19, 2016
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly PatientsEva González-Barca, Miguel A Canales, Antonio Salar, et al.
Pageof 25

Showing results (111-120 of 250) with videos related to

Sort By:
Pageof 25
Frontiers in Oncology|November 29, 2023
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myelomaLaura Rosiñol, Benjamin Hebraud, Albert Oriol, et al.
Haematologica|May 13, 2014
Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathiesLucía López-Corral, Luis Antonio Corchete, María Eugenia Sarasquete, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple MyelomaA Keith Stewart, Meletios A Dimopoulos, Tamás Masszi, et al.
Haematologica|November 8, 2011
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable diseaseLaura Rosiñol, Ramón García-Sanz, Juan José Lahuerta, et al.
Cancer|April 17, 2024
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myelomaAttaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, et al.
American Journal of Hematology|January 28, 2022
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trialEvangelos Terpos, Meletios A Dimopoulos, Mario Boccadoro, et al.
Haematologica|June 13, 2015
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trialRamón García-Sanz, Albert Oriol, María J Moreno, et al.
Cancer|January 31, 2013
Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab)Josep-Maria Ribera, Olga García, Carlos Grande, et al.
The Lancet. Oncology|July 13, 2016
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trialMaría-Victoria Mateos, Miguel-Teodoro Hernández, Pilar Giraldo, et al.
Acta Haematologica|May 19, 2016
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly PatientsEva González-Barca, Miguel A Canales, Antonio Salar, et al.
Pageof 25